

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

VOLUNTARY ANNOUNCEMENT GRANTING OF THE ISO 13485 CERTIFICATE

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business development of the Group.

The Board is pleased to announce that *Shenzhen Huakang Biomedical Engineering Co., Ltd (“深圳華康生物醫學工程有限公司”), being an indirect wholly-owned operating subsidiary of the Company, was granted with the International Organisation for Standardisation 13485 (“**ISO 13485**”) Certificate on 23 November 2020 for meeting the regulatory requirements of the design and development and production and sales of in-vitro diagnostic reagents (being medical devices used to diagnose diseases and physiological functions by obtaining clinical status information from testing specimens isolated from human blood, bodily fluids and tissue samples) relating to reproduction detection kits, biostaining reagents and enzyme-linked immunosorbent assay (ELISA) kits, all of which are kits or chemical substances used for detecting certain biological and/or chemical substances. Application for the ISO 13485 Certificate was part of the Group’s future plans in its product developments as disclosed in the prospectus dated 30 November 2018.

The ISO13485 certification is a standard published by the International Organisation for Standardisation which is applicable to all manufacturers, suppliers and distributors of medical devices and components as well as contract service providers. ISO13485 Certificate demonstrates the Group’s commitment to the international standard on product design and development for its production and sales. It also proves the Group’s efforts to offer advanced fertility solution by continually improving its capacity on research and development and quality management system

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 24 December 2020

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph , Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com

**For identification purpose only*